200 related articles for article (PubMed ID: 15831457)
21. Regulation of transforming growth factor-beta signaling by protein inhibitor of activated STAT, PIASy through Smad3.
Imoto S; Sugiyama K; Muromoto R; Sato N; Yamamoto T; Matsuda T
J Biol Chem; 2003 Sep; 278(36):34253-8. PubMed ID: 12815042
[TBL] [Abstract][Full Text] [Related]
22. SUMO-1 modification activated GATA4-dependent cardiogenic gene activity.
Wang J; Feng XH; Schwartz RJ
J Biol Chem; 2004 Nov; 279(47):49091-8. PubMed ID: 15337742
[TBL] [Abstract][Full Text] [Related]
23. PIASy-mediated repression of the Ets-1 is independent of its sumoylation.
Nishida T; Terashima M; Fukami K
Biochem Biophys Res Commun; 2006 Jul; 345(4):1536-46. PubMed ID: 16729975
[TBL] [Abstract][Full Text] [Related]
24. Modification of the erythroid transcription factor GATA-1 by SUMO-1.
Collavin L; Gostissa M; Avolio F; Secco P; Ronchi A; Santoro C; Del Sal G
Proc Natl Acad Sci U S A; 2004 Jun; 101(24):8870-5. PubMed ID: 15173587
[TBL] [Abstract][Full Text] [Related]
25. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation.
Tatham MH; Geoffroy MC; Shen L; Plechanovova A; Hattersley N; Jaffray EG; Palvimo JJ; Hay RT
Nat Cell Biol; 2008 May; 10(5):538-46. PubMed ID: 18408734
[TBL] [Abstract][Full Text] [Related]
26. PIASy is a SUMOylation-independent negative regulator of the insulin transactivator MafA.
Onishi S; Kataoka K
J Mol Endocrinol; 2019 Nov; 63(4):297-308. PubMed ID: 31614335
[TBL] [Abstract][Full Text] [Related]
27. RNF4-mediated SUMO-targeted ubiquitination relieves PARIS/ZNF746-mediated transcriptional repression.
Nishida T; Yamada Y
Biochem Biophys Res Commun; 2020 May; 526(1):110-116. PubMed ID: 32197837
[TBL] [Abstract][Full Text] [Related]
28. DPPA2/4 and SUMO E3 ligase PIAS4 opposingly regulate zygotic transcriptional program.
Yan YL; Zhang C; Hao J; Wang XL; Ming J; Mi L; Na J; Hu X; Wang Y
PLoS Biol; 2019 Jun; 17(6):e3000324. PubMed ID: 31226106
[TBL] [Abstract][Full Text] [Related]
29. Caveolin-3 undergoes SUMOylation by the SUMO E3 ligase PIASy: sumoylation affects G-protein-coupled receptor desensitization.
Fuhs SR; Insel PA
J Biol Chem; 2011 Apr; 286(17):14830-41. PubMed ID: 21362625
[TBL] [Abstract][Full Text] [Related]
30. PIASy inhibits virus-induced and interferon-stimulated transcription through distinct mechanisms.
Kubota T; Matsuoka M; Xu S; Otsuki N; Takeda M; Kato A; Ozato K
J Biol Chem; 2011 Mar; 286(10):8165-8175. PubMed ID: 21199872
[TBL] [Abstract][Full Text] [Related]
31. PIASy-mediated sumoylation of SREBP1c regulates hepatic lipid metabolism upon fasting signaling.
Lee GY; Jang H; Lee JH; Huh JY; Choi S; Chung J; Kim JB
Mol Cell Biol; 2014 Mar; 34(6):926-38. PubMed ID: 24379443
[TBL] [Abstract][Full Text] [Related]
32. Sumoylated SnoN represses transcription in a promoter-specific manner.
Hsu YH; Sarker KP; Pot I; Chan A; Netherton SJ; Bonni S
J Biol Chem; 2006 Nov; 281(44):33008-18. PubMed ID: 16966324
[TBL] [Abstract][Full Text] [Related]
33. PIASy represses CCAAT/enhancer-binding protein delta (C/EBPdelta) transcriptional activity by sequestering C/EBPdelta to the nuclear periphery.
Zhou S; Si J; Liu T; DeWille JW
J Biol Chem; 2008 Jul; 283(29):20137-48. PubMed ID: 18477566
[TBL] [Abstract][Full Text] [Related]
34. Systematic identification and analysis of mammalian small ubiquitin-like modifier substrates.
Gocke CB; Yu H; Kang J
J Biol Chem; 2005 Feb; 280(6):5004-12. PubMed ID: 15561718
[TBL] [Abstract][Full Text] [Related]
35. Proteasome-independent disruption of PML oncogenic domains (PODs), but not covalent modification by SUMO-1, is required for human cytomegalovirus immediate-early protein IE1 to inhibit PML-mediated transcriptional repression.
Xu Y; Ahn JH; Cheng M; apRhys CM; Chiou CJ; Zong J; Matunis MJ; Hayward GS
J Virol; 2001 Nov; 75(22):10683-95. PubMed ID: 11602710
[TBL] [Abstract][Full Text] [Related]
36. Role of SUMO in RNF4-mediated promyelocytic leukemia protein (PML) degradation: sumoylation of PML and phospho-switch control of its SUMO binding domain dissected in living cells.
Percherancier Y; Germain-Desprez D; Galisson F; Mascle XH; Dianoux L; Estephan P; Chelbi-Alix MK; Aubry M
J Biol Chem; 2009 Jun; 284(24):16595-16608. PubMed ID: 19380586
[TBL] [Abstract][Full Text] [Related]
37. Protein inhibitor of activated STAT3 (PIAS3) protein promotes SUMOylation and nuclear sequestration of the intracellular domain of ErbB4 protein.
Sundvall M; Korhonen A; Vaparanta K; Anckar J; Halkilahti K; Salah Z; Aqeilan RI; Palvimo JJ; Sistonen L; Elenius K
J Biol Chem; 2012 Jun; 287(27):23216-26. PubMed ID: 22584572
[TBL] [Abstract][Full Text] [Related]
38. Nucleus accumbens associated 1 is recruited within the promyelocytic leukemia nuclear body through SUMO modification.
Tatemichi Y; Shibazaki M; Yasuhira S; Kasai S; Tada H; Oikawa H; Suzuki Y; Takikawa Y; Masuda T; Maesawa C
Cancer Sci; 2015 Jul; 106(7):848-56. PubMed ID: 25891951
[TBL] [Abstract][Full Text] [Related]
39. Rod/Zw10 complex is required for PIASy-dependent centromeric SUMOylation.
Ryu H; Azuma Y
J Biol Chem; 2010 Oct; 285(42):32576-85. PubMed ID: 20696768
[TBL] [Abstract][Full Text] [Related]
40. The interaction of Piasy with Trim32, an E3-ubiquitin ligase mutated in limb-girdle muscular dystrophy type 2H, promotes Piasy degradation and regulates UVB-induced keratinocyte apoptosis through NFkappaB.
Albor A; El-Hizawi S; Horn EJ; Laederich M; Frosk P; Wrogemann K; Kulesz-Martin M
J Biol Chem; 2006 Sep; 281(35):25850-66. PubMed ID: 16816390
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
